[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Victor Chang Cardiac Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":53},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":5},"100579129","phase-2-acute-metabolic-effects-of-tirzepatide-in-type-1-diabetes-100579129",false,"NCT06820281","Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes","Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes: a Phase 2 Double Blinded Placebo Controlled Clinical Trial (TIRTLE2)","TIRTLE2","Inclusion Criteria:\n\n* age 18-65 years\n* BMI ≥ 27 kg\u002Fm2\n* HbA1c ≤ 9.0%\n* insulin delivery using an automated insulin delivery system\n* at least 2 years since diagnosis of type 1 diabetes\n\nExclusion Criteria:\n\n* TZP or GLP-1 receptor agonist in last 3 months; metformin or sodium glucose co-transporter 2 (SGLT2) inhibitor in the last 6 weeks; steroids, antipsychotics, immunosuppressants in the last 6 weeks.\n* Hypoglycemic unawareness or severe hypoglycemia last 6 months.\n* History of seizure disorder.\n* History of weight loss surgery.\n* eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m2.\n* Liver disease (known cirrhosis, LFTs \\> 3x upper limit of normal).\n* Active malignancy.\n* Pregnant, breastfeeding, planning pregnancy within 6 months, or not using adequate contraception.\n* History of cardiovascular disease, or coronary event or stroke in last 3 months\n* Hemoglobin level \\\u003C 13.5 g\u002FdL in men, \\\u003C 12.0 g\u002FdL in women","ALL","18 Years","65 Years",{"count":21,"type":22},44,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This study will examine the effects of Tirzepatide (TZP), a glucagon-like peptide 1 (GLP1) - gastric inhibitory peptide (GIP) co-agonist, on metabolism in type 1 diabetes (T1D). Research participants with T1D will undergo measures of insulin sensitivity, and hormone levels post-meal, post-hypoglycemia and during the overnight period. These measures will be performed prior to, and after 6 weeks of treatment with TZP or placebo.",[28],"Type 1 Diabetes Mellitus",[30,31,32,33,34,35,36,37,38,39,40],"Diabetes Mellitus, Type 1","Diabetes Mellitus","Autoimmune Diseases","Incretins","Physiological Effects of Drugs","Tirzepatide","Glucose Metabolism Disorders","Metabolic Diseases","Endocrine System Diseases","Overnutrition","Insulin Resistance","NOT_YET_RECRUITING","2026-05-17",{"date":44,"type":45},"2026-05-19","ACTUAL",{"date":47,"type":22},"2026-07-01",{"date":49,"type":22},"2027-12-31",{"name":51,"class":52},"Victor Chang Cardiac Research Institute","OTHER_GOV",""]